29
Participants
Start Date
August 31, 1999
Primary Completion Date
February 29, 2008
Study Completion Date
April 30, 2008
Acyclovir
Oral suspension 300 mg/m\^2/dose, 3 times per day (TID), for 6 months.
Placebo
Placebo identical to oral acyclovir suspension in appearance and taste.
Mount Sinai Hospital, New York
UNY Upstate Medical University Hospital - Pediatrics, Syracuse
Johns Hopkins Hospital, Baltimore
Carolinas Medical Center, Charlotte
Medical University of South Carolina, Charleston
University of Florida - College of Medicine - Jacksonville, Jacksonville
University of Alabama at Birmingham, Birmingham
Vanderbilt University, Nashville
Kosair Children's Hospital, Louisville
Nationwide Children's Hospital - Infectious Diseases, Columbus
Cincinnati Children's Hospital Medical Center, Cincinnati
Children's Hospital of Michigan - Pediatric Infectious Diseases, Detroit
The University of Chicago - Comer Children's Hospital - Infectious Diseases, Chicago
Washington University School of Medicine in St. Louis - Center for Clinical Studies, St Louis
Tulane University - Tulane Medical Center - Department of Pediatrics, New Orleans
Arkansas Children's Hospital, Department of Infectious Diseases, Little Rock
Cook Children's Infectious Disease Services, Fort Worth
University of Texas Health Science Center San Antonio - Pediatrics - Immunology & Infectious Disease, San Antonio
Rady Children's Hospital San Diego, San Diego
Seattle Children's Hospital - Infectious Diseases, Seattle
Stanford University School of Medicine, Stanford
Maine Medical Center - Department of Pediatric Specialty Care - Infectious Disease, Portland
University of Mississippi, Jackson
MetroHealth Medical Center - Pediatric Infectious Disease, Cleveland
Oregon Health and Science University, Portland
Rhode Island Hospital, Providence
University of Texas Southwestern Medical Center, Dallas
University of Alberta - Aberhart Centre - Pediatrics, Edmonton
National Institute of Allergy and Infectious Diseases (NIAID)
NIH